ACADIA Pharmaceuticals is trading 4.61% up at $22.46 after reporting third-quarter results on November 4, 2026, that exceeded analyst expectations. - Revenue was $342 million; DAYBUE sales hit a record $140 million, up 39% year over year. - ACADIA raised 2026 DAYBUE sales guidance to $505–$520 million. - RBC raised its price target to $38 from $36 on November 5, citing DAYBUE uptake; broader-market and biotech weakness does not appear to explain the gain.